主页文献库搜索
Prognostic value of soft tissue metastasis (STM) in stage D2 and stage D3 pro...

Madan(R A),Xia(Q),Hwang(S),Chang(V T),Zhon... J Clin Oncol 0000-00-00

...Alkaline Phosphatase (ALK), PSA, bone scan (BSD2), CT scan (CTD2), race. At time of D3, we documented status of bone sca...

Brigatinib Effective in ALK+ NSCLC.

Cancer Discov 0000-00-00

...ALK inhibitor brigatinib is active in patients with ALK-rearranged non-small cell lung cancer. Patients who had previous...

Clinicopathological Characteristics and Survival of ALK, ROS1 and RET rearran...

Song(Zhengbo),Yu(Xinmin),Zhang(Yiping) Cancer Biol Ther 0000-00-00

...ALK, ROS1 and RET rearrangements in non-adenocarcinoma NSCLC patients.,ALK, ROS1 and RET rearrangements were screened by...

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Develo...

Noronha(Vanita),Ramaswamy(Anant),Patil(Vij... PLoS One 0000-00-00

To evaluate the performance and treatment profile of advanced EML4-ALK positive Non-small cell lung cancer (NSCLC) patie...

ALK alterations and inhibition in lung cancer.

Le(Tri),Gerber(David E) Semin Cancer Biol 0000-00-00

...ALK) gene. In an astoundingly brief period following the recognition of ALK-positive NSCLC, details of the biology, clin...

The use of cellular thermal shift assay (CETSA) to study Crizotinib resistanc...

Alshareef(Abdulraheem),Zhang(Hai-Feng),Hua... Sci Rep 0000-00-00

...ALK binding in a panel of ALK(+) cell lines, and correlated the findings with the ALK structure and its interactions wit...

Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasiv...

Shin(Dong Hoon),Lee(Donghoon),Hong(Dong Wa... Oncotarget 0000-00-00

...ALK fusion in additional two cases with NRG1 fusions. When comparing overall survival (OS) according to the presence of ...

Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutation...

Latteyer(Soeren),Tiedje(Vera),König(Kathar... Endocrine 0000-00-00

...ALK (6/30), NRAS (4/30), ATRX (3/30), BRAF (2/30), HRAS (2/30), KRAS (1/30). In 17/30 ATC (54 %) mutations were found in...

Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therap...

Qiao(Huan),Lovly(Christine M) Cancer Discov 0000-00-00

...ALK inhibitors in ALK-rearranged non-small cell lung cancer and found that an increased frequency and distinct spectrums...

Primary gastric anaplastic lymphoma kinase-negative anaplastic large-cell lym...

Tian(Chen),Zhang(Yizhuo) Onco Targets Ther 0000-00-00

...ALK-negative ALCLs is usually worse than ALK-positive ALCLs. In this case, the patient was not responsive to a multidrug...

上一页 637 638 639 640 641 642 643 644 645 下一页 641 / 共 646

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: product@genelibs.com